Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
Beijing-based Inno Medicine has raised nearly RMB 800 million (roughly $110 million-plus) in a Series D financing, giving the Chinese nanomedicine developer substantial new capital as its two flagship programs move deeper into global clinical…